An ultra-rare-disease focus allows Alexion to capture substantial pricing power.
We are maintaining our $170 fair value estimate for Alexion Pharmaceuticals following the company’s third-quarter results. Management narrowed top-line guidance to the high end of its original range thanks to strong underlying demand for Soliris but reduced full-year earnings guidance to reflect charges related to its restructuring plan. As previously announced, Alexion divested itself of several pipeline drugs and is closing a manufacturing plant to allow for more focused cost discipline and re...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.